PerryPGuaglianoneMD

PubMed

• 57 citations
  Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a r...
  Roy S. Herbst, Mary W. Redman, Edward S. Kim, Thomas J. Semrad, Lyudmila Bazhenova, Gregory A. Masters, Kurt R. Oettel, Perry Guaglianone, Christopher M. Reynolds, Ana...> ;The Lancet. Oncology. 2018 Jan 1
• 41 citations
  A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cer...
  Charles A. Kunos, Wei Deng, Dawn M. Dawson, Jayanthi S. Lea, Kristine M. Zanotti, Heidi J. Gray, David Bender, Perry P. Guaglianone, Jori S. Carter, Kathleen N. Moore> ;International Journal of Gynecological Cancer. 2015 Mar 10
• Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
  Brahmer JR, Lee JW, Traynor AM, Hidalgo MM, Kolesar JM, Siegfried JM, Guaglianone PP, Patel JD, Keppen MD, Schiller JH> ;Eur. J. Cancer. 2014-01-01
• 87 citations
  Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420
  Stephen K. Williamson, James J. Moon, Chao H. Huang, Perry P. Guaglianone, Michael LeBlanc, Gregory T. Wolf, Susan G. Urba> ;Journal of Clinical Oncology. 2010 Jul 10
• 42 citations
  Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
  Primo N. Lara, Kari Chansky, Angela M. Davies, Wilbur A. Franklin, Paul H. Gumerlock, Perry Guaglianone, James N. Atkins, Nichole C. Farneth, Philip C. Mack, John Crow...> ;Journal of Thoracic Oncology. 2006 Nov 1
• A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial.
  Williamson SK, Moon J, Huang CH, Guaglianone P, Wolf GT, Urba SG> ;J. Clin. Oncol.. 2006-06-20
• ECOG 3503: A pilot study to determine if downstream markers of EGFR linked signaling pathways predict response to erlotinib (OSI-774) in the first-line treatment of pa...
  Kolesar J, Brahmer J, Li S, Guaglianone P, Patel J, Keppen M, Hidalgo M, Carbone D, Siegfried J, Schiller J> ;J. Clin. Oncol.. 2006-06-20
• 61 citations
  Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).
  Perry Guaglianone, Kenneth K. Chan, Eduardo DelaFlor-Weiss, Rosemarie Hanisch, Susan Jeffers, Desh Sharma, Franco M. Muggia> ;Investigational New Drugs. 1994 Jan 1
• 18 citations
  Synthesis and Characterization of Biotin-Labeled Nucleotide Analogs
  Mary Shimkus, Perry Guaglianone, Timothy M. Herman> ;DNA. 1986 Jun 1
• High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary.
  Gill, I., Guaglianone, P., Grunberg, S. M., Scholz, M., Muggia, F. M.> ;Anticancer Res. 1991 May 01
• Join now to see all